6:30 am Check In & Registration for Workshop B

7:00 am Workshop B: Exploring the Current & Future Use of Generative AI, Machine Learning & Automation to Streamline Environmental, Health & Safety Success

• Steven Laflin Principal SHE Program Manager, Industrial Hygiene, Genentech

8:55 am Chair’s Opening Remarks

Managing Consistent EHS Standards in Fast-Paced Biopharma Environments – Maintaining Proactivity over Reactivity

9:00 am Proactive EHS Risk Reduction Strategies in Plasma Manufacturing: Reducing Injury Potential and Improving Systems

• Obed Varela Senior Director & Head of Environment, Health, & Safety Plasma Derived Therapies, Takeda

9:30 am Roundtable Discussion: Navigating The Transition From R&D to Large-Scale Manufacturing in Biopharma

10:00 am Morning Break & Networking

Achieving A Safety Minded Culture & Total Employee Engagement In EHS Processes

11:00 am Promoting a Positive Safety Culture in Biopharma: Practical Actions for Leadership, Engagement, and Success

• Joe Hess Sr. Director EHS&S, Gilead Sciences

11:30 am Creating a Safety-Minded Culture in Biopharma: Strategies for Effective EHS Integration

• Richard Silverman Principal Consultant, The British Standards Institution

12:00 pm Lunch

1:00 pm Panel Discussion: Moving Away from the ‘Police Perception’ & Getting Buy-In for Success

• Cristina Cavalheiro Commercial & ITO Environment, Health & Safety Leader, Cytiva
• Blair Michael Head of EHS, Lonza
• Andrea Mims Senior Director Health, Safety, Environmemtal, Eli Lilly

Eliminating Biopharma Biological & Chemical Risks For a Zero-Incident Laboratory Space

2:00 pm Roundtable Discussion: What Is Acceptable Versus Unacceptable Risk With The Use Of Prion-Like Proteins?

• Allison Liljedahl Senior Manager, Program Biosafety, Genentech

2:30 pm Afternoon Break

3:00 pm Developing a Large Scale Biosafety Program for Viral Vector Manufacturing

• Mike McCarthy Senior Manager - Environmental Health Safety & Sustainability , Biological Safety Officer, Vertex Pharmaceuticals

3:30 pm Best Practice for Generating an EHS Protocol in R&D Facilities with Uncharacterized APIs

• Paul Ryan Director - Environment Health & Safety ,Occupational Sustainability ,Research and development, Bristol Myers Squibb

4:00 pm Exploring Eli Lilly’s Chemical Hygiene Plan for Addressing Uncharacterised APIs in R&D

• Andrea Mims Senior Director Health, Safety, Environmemtal, Eli Lilly

4:30 pm Developing CAR-T Therapies – Lessons Learned from an EHS Perspective

• Edward David Associate Director, Bristol Myers Squibb

5:00 pm Chairs Closing Remarks

5:10 pm End of Day Two